Nature, Published online: 01 July 2026; doi:10.1038/s41586-026-10718-x
Monotherapy with the HIF-2α inhibitor casdatifan achieves meaningful, durable responses linked to HIF-2α biology with manageable safety in the treatment of individuals with clear cell renal cell carcinoma.Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
Nature, Published online: 01 July 2026; doi:10.1038/s41586-026-10718-xMonotherapy with the HIF-2α inhibitor casdatifan achieves meaningful, durable responses linked to HIF-2α biology with manageable safety in the treatment of individua…